| 501 |
Apheresis |
Allogeneic
|
Plasma Cell Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
62 |
| 502 |
Apheresis |
Allogeneic
|
Hodgkin’s Disease
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
34 |
| 503 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
France
|
20 |
| 504 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
40 |
| 505 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
51 |
| 506 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
58 |
| 507 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2026
|
Standard Therapy
|
Ukraine
|
45 |
| 508 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Ukraine
|
41 |
| 509 |
Apheresis |
Allogeneic
|
Hodgkin’s Disease
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
44 |
| 510 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
47 |
| 511 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Colombia
|
57 |
| 512 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
72 |
| 513 |
Apheresis |
Allogeneic
|
EBV-positive nodal T- and NK-cell lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
68 |
| 514 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia, Myelodysplasia-Related
|
Hematology
|
2026
|
Standard Therapy
|
Russia Federation
|
48 |
| 515 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Finland
|
69 |
| 516 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
67 |
| 517 |
Apheresis |
Allogeneic
|
Large Cell Anaplastic Lyphoma ALK
|
Hematology
|
2026
|
Standard Therapy
|
Serbia
|
13 |
| 518 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
74 |
| 519 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2026
|
Standard Therapy
|
Lithuania
|
64 |
| 520 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
67 |
| 521 |
Apheresis |
Allogeneic
|
Acute Undifferentiated Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
16 |
| 522 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Czechia
|
53 |
| 523 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
68 |
| 524 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
India
|
18 |
| 525 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
50 |
| 526 |
Apheresis |
Allogeneic
|
Chronic myelomonocytic leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Lithuania
|
66 |
| 527 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
51 |
| 528 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
41 |
| 529 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
72 |
| 530 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
70 |
| 531 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
61 |
| 532 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Lithuania
|
62 |
| 533 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
62 |
| 534 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
61 |
| 535 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
58 |
| 536 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
India
|
2 |
| 537 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
21 |
| 538 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
63 |
| 539 |
Apheresis |
Autologous
|
Diffuse Large B-cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
71 |
| 540 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
61 |
| 541 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
65 |
| 542 |
Apheresis |
Autologous
|
T-Cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
64 |
| 543 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
70 |
| 544 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
59 |
| 545 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
66 |
| 546 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
61 |
| 547 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
53 |
| 548 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
France
|
26 |
| 549 |
Apheresis |
Allogeneic
|
Inherited Metabolic Disorder
|
Hematology
|
2026
|
Standard Therapy
|
France
|
50 |
| 550 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
70 |
| 551 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
France
|
70 |
| 552 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Argentina
|
30 |
| 553 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
74 |
| 554 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
61 |
| 555 |
Apheresis |
Allogeneic
|
Hyper IgE Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
11 |
| 556 |
Apheresis |
Allogeneic
|
AML FLT3+
|
Hematology
|
2026
|
Standard Therapy
|
Croatia
|
61 |
| 557 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
61 |
| 558 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
58 |
| 559 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Iran
|
3 |
| 560 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
59 |
| 561 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
58 |
| 562 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
United Kingdom
|
10 |
| 563 |
Apheresis |
Allogeneic
|
Lymphoma – Peripheral T cell
|
Hematology
|
2026
|
Standard Therapy
|
United Kingdom
|
53 |
| 564 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
48 |
| 565 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
13 |
| 566 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
58 |
| 567 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
69 |
| 568 |
Apheresis |
Allogeneic
|
Peripheral T Cell Lymphoma With Haemophagocytic Lymphohistiocytosis
|
Hematology
|
2026
|
Standard Therapy
|
United Kingdom
|
52 |
| 569 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
62 |
| 570 |
Apheresis |
Allogeneic
|
T-Cell Prolymphocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
72 |
| 571 |
Apheresis |
Allogeneic
|
Myelodysplastic Disorder
|
Hematology
|
2026
|
Standard Therapy
|
Russian Federation
|
51 |
| 572 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
64 |
| 573 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
62 |
| 574 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
49 |
| 575 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
75 |
| 576 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
68 |
| 577 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
58 |
| 578 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
52 |
| 579 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
69 |
| 580 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
20 |
| 581 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
65 |
| 582 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Belgium
|
34 |
| 583 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
67 |
| 584 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
69 |
| 585 |
Apheresis |
Allogeneic
|
T-Cell Acute lymphoblastic leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Netherlands
|
21 |
| 586 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
70 |
| 587 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
68 |
| 588 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
16 |
| 589 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
65 |
| 590 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
61 |
| 591 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
65 |
| 592 |
Apheresis |
Autologous
|
Central Nervous System Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
65 |
| 593 |
Apheresis |
Autologous
|
Diffuse Large B-cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
45 |
| 594 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
61 |
| 595 |
Apheresis |
Allogeneic
|
B-cell Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
21 |
| 596 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
65 |
| 597 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
68 |
| 598 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Ukraine
|
5 |
| 599 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Hungary
|
57 |
| 600 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
30 |